Details for New Drug Application (NDA): 206181

NDA 206181 describes VORICONAZOLE, which is a drug marketed by Amneal Pharms, Hainan Poly, Novel Labs Inc, Rising, Almaject, Aspiro, Chartwell Rx, Eugia Pharma, Gland Pharma Ltd, Meitheal, Norvium Bioscience, Sandoz Inc, Slate Run Pharma, UBI, Zydus Pharms, Ajanta Pharma Ltd, Aurobindo Pharma Ltd, Cadila, Epic Pharma Llc, Glenmark Pharms Ltd, Mylan Pharms Inc, Prinston Inc, and Teva Pharms, and is included in twenty-six NDAs. It is available from thirty-three suppliers. Additional details are available on the VORICONAZOLE profile page.

The generic ingredient in VORICONAZOLE is voriconazole. There are fourteen drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the voriconazole profile page.

Summary for 206181

Tradename:	VORICONAZOLE
Applicant:	Ajanta Pharma Ltd
Ingredient:	voriconazole
Patents:	0

Pharmacology for NDA: 206181

Mechanism of Action

Cytochrome P450 2C19 Inhibitors Cytochrome P450 2C9 Inhibitors Cytochrome P450 3A4 Inhibitors

Medical Subject Heading (MeSH) Categories for 206181

14-alpha Demethylase Inhibitors

Antifungal Agents

Cytochrome P-450 CYP3A Inhibitors

Suppliers and Packaging for NDA: 206181

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
VORICONAZOLE	voriconazole	TABLET;ORAL	206181	ANDA	Major Pharmaceuticals	0904-7024	0904-7024-04	30 BLISTER PACK in 1 CARTON (0904-7024-04) / 1 TABLET in 1 BLISTER PACK
VORICONAZOLE	voriconazole	TABLET;ORAL	206181	ANDA	Ajanta Pharma USA Inc.	27241-062	27241-062-03	30 TABLET in 1 BOTTLE (27241-062-03)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	50MG
Approval Date:	May 24, 2016	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	200MG
Approval Date:	May 24, 2016	TE:	AB	RLD:	No

Complete Access Available with Subscription